Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Jeryl Lynn

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    37 result(s) found for: Jeryl Lynn. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2011-004485-15 Sponsor Protocol Number: 110876 Start Date*: 2015-06-25
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase IIIb, open, randomized study to evaluate non-inferiority of GSK Biologicals’ measles-mumps-rubella-varicella vaccine versus co-administration of GSK Biologicals’ Priorix™ and Varilrix™ in h...
    Medical condition: Measles, mumps, rubella and varicella diseases
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-005882-19 Sponsor Protocol Number: 109995 Start Date*: 2015-06-25
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: Non-inferiority of GSK Biologicals’ measles-mumps-rubella-varicella (MMRV) vaccine 208136 vs Priorix™ and Priorix™ coadministered with Varilrix™ (comparator) and to evaluate non-inferiority of Prio...
    Medical condition: Measles, mumps, rubella and varicella diseases
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2004-005123-18 Sponsor Protocol Number: 104020 Start Date*: 2005-04-15
    Sponsor Name:GlaxoSmithKline
    Full Title: A phase III, partially blind, randomised, primary vaccination study to assess the immunogenicity and safety of three different lots of GlaxoSmithKline (GSK) Biologicals’ live attenuated measles-mum...
    Medical condition: Active immunization of healthy children during their second year of life against measles, mumps, rubella and varicella diseases.
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-004371-11 Sponsor Protocol Number: 103388 & 104690 Start Date*: 2005-07-12
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase IIIB, partially blind, randomized study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals’ measles-mumps-rubella-varicella vaccine (MeMuRu-OKA) given to healthy child...
    Medical condition: Active immunization of healthy children during their second year of life against measles, mumps, rubella and varicella diseases.
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2005-005944-22 Sponsor Protocol Number: 106670 Start Date*: 2006-02-21
    Sponsor Name:GlaxoSmithKline GmbH & Co. KG
    Full Title: Open, multicenter, randomised, controlled phase IIIb study evaluating the immunogenicity and safety of subcutaneous versus intramuscular administration of GlaxoSmithKline Biologicals’ combined meas...
    Medical condition: Active immunization of healthy children aged 11 to 21 months against measles, mumps, rebella and varicella diseases
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-001443-13 Sponsor Protocol Number: V221-027 Start Date*: 2017-04-10
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, Varicella (MMRV) Vaccine Made with an Altern...
    Medical condition: Active immunization for the prevention of measles, mumps, rubella, and varicella
    Disease: Version SOC Term Classification Code Term Level
    19.1 10021881 - Infections and infestations 10047461 Viral infection PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2004-005263-19 Sponsor Protocol Number: 104389 Start Date*: 2005-05-03
    Sponsor Name:GSK Biologicals
    Full Title: A phase III, blinded, randomised, controlled study to evaluate the immunogenicity and safety of three production lots of GlaxoSmithKline Biologicals’ combined measles-mumps-rubella-varicella (MeMuR...
    Medical condition: Active immunization of healthy children during their second year of life against measles, mumps, rubella and varicella diseases.
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-000454-18 Sponsor Protocol Number: 110058 Start Date*: 2017-07-10
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase II randomized, observer blind, multicenter study of GlaxoSmithKline (GSK) Biologicals’ combined measles-mumps-rubella-varicella vaccine (MMRV) versus ProQuad, according to a one dose schedu...
    Medical condition: Healthy volunteers (Use of the candidate MMRV vaccine for immunization of healthy children 12 - 14 months of age against measles, mumps, rubella and varicella).
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-005860-31 Sponsor Protocol Number: 111870 Start Date*: 2015-06-25
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: Immunogenicity of GlaxoSmithKline Biologicals’ MMR vaccine (209762) vs. M-M-R® II, when co-administered with hepatitis A, varicella and pneumococcal conjugate vaccines to children 12-15 months of age
    Medical condition: Diseases caused by measles, mumps, rubella and varicella viruses
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-002468-88 Sponsor Protocol Number: MRV02C Start Date*: 2007-10-12
    Sponsor Name:Sanofi Pasteur MSD SNC
    Full Title: An open-label, randomised, comparative, multi-centre study of the immunogenicity and safety of a 2-dose regimen of ProQuad® manufactured with rHA administered to healthy children from 9 months of age
    Medical condition: Measles, mumps, rubella and varicella vaccine administered to healthy children from 9 months of age
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2019-003306-27 Sponsor Protocol Number: B7471012 Start Date*: 2020-12-03
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE GIVEN AS A SERIES OF 2 INFANT DOSES AND 1 TODDLER DOSE IN HEALTHY I...
    Medical condition: Pneumococcal Infections
    Disease: Version SOC Term Classification Code Term Level
    21.1 10042613 - Surgical and medical procedures 10069578 Pneumococcal immunisation PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: NO (Completed) CZ (Completed) EE (Completed) FI (Completed) PL (Completed) SK (Completed) DK (Completed) BE (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-003318-81 Sponsor Protocol Number: 111846 Start Date*: 2008-11-17
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase IV, open, randomized, controlled study to demonstrate the non-inferiority of co-administration of GSK Biologicals’ live attenuated measles-mumps-rubella-varicella vaccine and Baxter’s Neiss...
    Medical condition: Active immunization of healthy children during their second year of life against measles, mumps, rubella, varicella and Neisseria meningitidis C diseases
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-001934-42 Sponsor Protocol Number: 107706 Start Date*: 2006-07-26
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase IIIa open, randomised, controlled study to assess the safety, reactogenicity and immunogenicity induced by a booster dose of GlaxoSmithKline (GSK) Biologicals 10-valent pneumococcal conjuga...
    Medical condition: Booster vaccination against Streptococcus pneumoniae and active immunization against measles, mumps, rubella and varicella diseases in children during the second year of life.
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2011-005881-38 Sponsor Protocol Number: 108760 Start Date*: 2015-06-25
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase II, randomized, double-blind study of Priorix-Tetra (combined measles-mumps-rubella-varicella vaccine), one lot using new measles and rubella working seeds and one lot using old working see...
    Medical condition: Measles, mumps, rubella and varicella diseases
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-003672-36 Sponsor Protocol Number: 115231,MMR159 Start Date*: 2014-10-09
    Sponsor Name:GlaxoSmithKline Biologicals S.A.
    Full Title: A Phase IIIA, observer-blind, randomized study to evaluate non-inferiority of a second dose of GSK Biologicals’ measles-mumps-rubella vaccine vs. a second dose of Merck & Co., Inc.’s MMR vaccine wh...
    Medical condition: Healthy volunteers (Active immunization against measles, mumps and rubella diseases of healthy subjects, 7 years of age and older).
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004865 10069547 Mumps immunization LLT
    17.1 100000004862 10039276 Rubella with unspecified complications LLT
    17.1 100000004865 10069545 Measles immunization LLT
    17.1 100000004862 10039274 Rubella with other specified complication LLT
    17.1 100000004865 10069564 Rubella immunization LLT
    17.1 100000004862 10028274 Mumps with other specified complication LLT
    17.1 100000004862 10027021 Measles without mention of complication LLT
    17.1 100000004862 10027020 Measles with unspecified complication LLT
    17.1 100000004858 10027022 Measles-like rash LLT
    Population Age: Children, Under 18, Adults Gender: Male, Female
    Trial protocol: SK (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2004-002676-41 Sponsor Protocol Number: 100388,103494,104105,104106 Start Date*: 2005-05-23
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: Blinded, randomised, controlled, multicenter study to evaluate the clinical efficacy against varicella disease of GlaxoSmithKline Biologicals’ live attenuated varicella vaccine (Varilrix) given on ...
    Medical condition: Healthy children between 12-22 months (including the day before the 23-month birthday) of age at the time of vaccination with no history of measles, mumps, rubella and varicella diseases/vaccination.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10028257 Mumps PT
    14.1 10021881 - Infections and infestations 10046980 Varicella PT
    14.1 10021881 - Infections and infestations 10039252 Rubella PT
    14.1 10021881 - Infections and infestations 10027011 Measles PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: SE (Completed) LT (Completed) SK (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-004905-26 Sponsor Protocol Number: 115649 Start Date*: 2012-10-10
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: Immunogenicity and safety study of GSK Biologicals’ Priorix® vaccine (209762) at an end of shelf-life potency compared to Merck & Co., Inc.’s MMR vaccine when both are given on a 2-dose schedule to...
    Medical condition: Healthy volunteers (Active immunization against measles, mumps and rubella diseases of healthy children in their second year of life).
    Disease: Version SOC Term Classification Code Term Level
    17.0 10021881 - Infections and infestations 10028257 Mumps PT
    17.0 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    17.0 10021881 - Infections and infestations 10039252 Rubella PT
    17.0 10021881 - Infections and infestations 10027011 Measles PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed) CZ (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-004638-32 Sponsor Protocol Number: 115158 Start Date*: 2015-06-11
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase IIIA, observer-blind, randomized study to evaluate non-inferiority of a second dose of GSK Biologicals’ measles-mumps-rubella vaccine vs. a second dose of Merck & Co., Inc.’s MMR vaccine wh...
    Medical condition: Healthy volunteers (Active immunization against measles, mumps and rubella diseases of healthy subjects, 4 to 6 years of age).
    Disease: Version SOC Term Classification Code Term Level
    18.0 10021881 - Infections and infestations 10028257 Mumps PT
    18.0 10022891 - Investigations 10059638 Mumps antibody test PT
    18.0 10021881 - Infections and infestations 10027015 Measles like illness LLT
    18.0 10021881 - Infections and infestations 10039270 Rubella viral infections HLT
    18.0 10021881 - Infections and infestations 10027011 Measles PT
    18.0 100000004858 10027022 Measles-like rash LLT
    18.0 10022891 - Investigations 10039261 Rubella immunity (confirmed) LLT
    18.0 10021881 - Infections and infestations 10028262 Mumps like illness LLT
    18.0 10021881 - Infections and infestations 10039252 Rubella PT
    18.0 10022891 - Investigations 10060066 Measles antibody PT
    18.0 10022891 - Investigations 10039255 Rubella antibodies not present LLT
    18.0 10021881 - Infections and infestations 10028268 Mumps viral infections HLT
    18.0 10022891 - Investigations 10039259 Rubella antibody test PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-006161-18 Sponsor Protocol Number: 115650 Start Date*: 2014-09-25
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase IIIA, randomized, observer-blind, controlled, multinational study to evaluate the safety and immunogenicity of GSK Biologicals' MMR vaccine (209762) (Priorix®) compared to Merck & Co., Inc....
    Medical condition: Healthy volunteers (Active immunization against measles, mumps and rubella diseases in healthy children, 12 to 15 months of age)
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004865 10069547 Mumps immunization LLT
    18.0 100000004862 10039276 Rubella with unspecified complications LLT
    18.0 100000004862 10039274 Rubella with other specified complication LLT
    18.0 100000004865 10069545 Measles immunization LLT
    18.0 100000004865 10069564 Rubella immunization LLT
    18.0 100000004862 10028276 Mumps with unspecified complication LLT
    18.0 100000004862 10027015 Measles like illness LLT
    18.0 100000004862 10028275 Mumps with other specified complications LLT
    18.0 100000004862 10027021 Measles without mention of complication LLT
    18.0 100000004862 10027020 Measles with unspecified complication LLT
    18.0 100000004858 10027022 Measles-like rash LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: EE (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2011-004891-12 Sponsor Protocol Number: 115648 Start Date*: 2012-11-02
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase IIIA, randomized, observer-blind, controlled, multinational consistency study to evaluate the immunogenicity and safety of GSK Biologicals' MMR vaccine (209762) (Priorix®) compared to Merck...
    Medical condition: Healthy volunteers (Active immunization against measles, mumps and rubella diseases of healthy children in their second year of life).
    Disease: Version SOC Term Classification Code Term Level
    18.0 10021881 - Infections and infestations 10028257 Mumps PT
    18.0 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    18.0 10021881 - Infections and infestations 10039252 Rubella PT
    18.0 10021881 - Infections and infestations 10027011 Measles PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: EE (Completed) FI (Completed) ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 01 01:19:14 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA